Diagnosing Dx

Diagnosing Dx

By Elevra ConsultingScienceLife Sciences
Download on the App Store

Diagnosing Dx episodes

  • How Pictor Is Scaling Proteomics for Faster, Smarter Testing – Janine McMurdie

    This week on Diagnosing Dx, I’m joined by Janine McMurdie, Chief Commercial Officer at Pictor, a company unlocking the next wave of innovation in diagnostics through proteomics.

    With a career spanning industry giants like Amgen and IonTorrent, Janine shares what it takes to lead in a fast-evolving space - where scalability, speed, and strategy matter more than ever.

    We dive into how Pictor’s flexible platform is pushing proteomics toward its tipping point, why patient-centric design is critical, and how regulatory momentum is working in their favour.

     

    🔥 What You’ll Learn:

    • Why proteomics is the "new genomics" in diagnostics

    • How Pictor is building a fast, scalable, and cost-effective platform

    • The impact of recent regulatory changes on startup strategy

    • How strong leadership and patient focus shape product success

     

    🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of Diagnostics.

    50 min
  • Developing Biomarker strategies and the future of Prognostics - Sam Agus

    This week on Diagnosing Dx, I’m joined by Dr. Sam Agus, a neurologist and diagnostics innovator with over 20 years of experience in clinical trials, biomarker development, and early-stage ventures.

     

    In this candid conversation, Sam shares the hard truths about why diagnostics companies struggle for funding, why prognostics are quietly becoming the next frontier, and how early partnerships - especially with pharma, can make or break a startup.


    With deep insights from his work in chronic kidney disease, Alzheimer’s, and early diagnostics ventures, this episode is essential listening for anyone building, backing, or navigating the Dx space.

     

    🔥 What You’ll Learn:

     

    • Why prognostic biomarkers are shaping the future of diagnostics

    • How early-stage partnerships with pharma drive commercial success

    • The biggest funding challenges facing Dx startups today

    • What investors really want in a diagnostics pitch


    Whether you're a founder, investor, or clinical innovator, Sam’s experience offers practical insight into the future of diagnostics, and what it takes to get there.

     

    🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of Diagnostics.

    57 min
  • MDx innovation and culture and the future of diagnostics R&D – Kim Langone

    This week on Diagnosing Dx, we’re joined by Kim Langone, SVP of R&D at Fellow Health, and former 10th employee at Genomic Health, where for 19 years, she played a pivotal role in developing Oncotype DX, a landmark diagnostic test for breast cancer.

     

    With 24 years of experience in molecular diagnostics, Kimshares what it takes to build breakthrough science in a startup, scale it, and navigate the evolving challenges of today’s diagnostics landscape.

     

    🔥 In This Episode, You’ll Learn:

     • How early-stage culture and leadership shape long-term innovation

    • What it’s like to build diagnostics from scratch—then scale with impact

    • Why commercialization and reimbursement strategy are non-negotiable

    • What scientists and R&D leaders need to consider when joining startups vs. corporates


    Whether you're scaling science, leading R&D, or enteringthe diagnostics field, Kim offers hard-earned insights for building a lasting career—and technology that truly matters.

     

    🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of Diagnostics.

    57 min
  • Regulatory strategy for startups in Dx and mistakes to avoid – Heinz Steneberg

    This week on Diagnosing Dx, we’re joined by Heinz Steneberg, President and CEO of MDSS, for a deep dive into the role of Regulatory Strategy in Diagnostics and MedTech startups.


    From early-stage planning to FDA engagement, we cover the decisions that make or break go-to-market timelines - and how emerging models are shaping the regulatory future.


    🔥 What You’ll Learn:

    • How to use FDA pre-submissions to clarify your path to approval

    • What it takes to secure Breakthrough Designation - and why it matters

    • The most common regulatory missteps made by startups

    • How AI and direct-to-consumer models are shifting regulatory expectations

    • What support MDSS provides to help startups navigate compliance


    Whether you're a founder, operator, or innovator in diagnostics, this episode delivers clear, practical insights to help you build smarter - and faster.


    🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of Diagnostics.

    52 min

About Diagnosing Dx

From the publisher's feed

How do we transform cutting-edge scientific discoveries into life-saving diagnostics?